



英文版仅为中文版之翻译，若中英歧义，请以中文版为准。

The English translation is for reference purposes only.

In the event of any discrepancy between the Chinese original and the English translation, the Chinese original shall prevail.

2024 第三季度报告

The Third Quarter Report in 2024

甘李药业股份有限公司
GAN & LEE PHARMACEUTICALS.
股票代码：603087
STOCK CODE: 603087

目 录

Contents

重要内容提示 Important Notes	3
一、主要财务数据 I Major Financial Data	4
二、股东信息 II Shareholder Information	12
三、季度财务报表 III Quarterly financial statements	16

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。

The Board of Directors and all Company directors warrant that there are no false records, misleading statements, or material omissions in this announcement. They are legally responsible for the truthfulness, accuracy, and completeness of its contents.

重要内容提示：

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。

公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)保证季度报告中财务信息的真实、准确、完整。

第三季度财务报表是否经审计

否

Important Notes:

The Board of Directors, the Supervisory Committee and directors, supervisors, and senior management of the Company guarantee the truthfulness, accuracy and completeness of the contents of the quarterly report, and that there are no false records, misleading statements or material omissions, for which they shall be individually and jointly liable.

The legal representative, chief accountant, and head of accounting department (accounting supervisor) hereby certify that the financial report set out in the quarterly report is true, accurate and complete.

Whether the third quarter financial statements are audited

No

主要财务数据

Major Financial Data



一、主要财务数据

I Major Financial Data

(一) 主要会计数据和财务指标

(I) Major accounting data and financial indicators

单位：元 币种：人民币
Unit: RMB

项目 Item	本报告期 Current reporting period	本报告期比上年同期增 减变动幅度(%) Change in the current reporting period over the same period of the previous year (%)	年初至报告期末 Beginning of the year to the end of the reporting period	年初至报告期末比上年同期 增减变动幅度(%) Change from the beginning of the year to the end of the reporting period over the same period of the previous year (%)
营业收入 Operating income	930,113,241.87	37.61	2,245,006,087.12	17.81
归属于上市公司股东的净利润 Net profit attributable to shareholders of the listed company	208,361,150.62	57.47	507,265,245.69	90.36
归属于上市公司股东的扣除非经 常性损益的净利润 Net profit attributable to shareholders of the listed company after the deduction of non-recurring gains and losses	183,839,042.86	50.79	310,745,817.10	38.64
经营活动产生的现金流量净额 Net cash flows from operating activities	不适用 N/A	不适用 N/A	465,340,293.85	不适用 N/A
基本每股收益(元/股) Basic earnings per share (RMB per share)	0.35	45.83	0.85	80.85
稀释每股收益(元/股) Diluted earnings per share (RMB per share)	0.35	45.83	0.85	80.85
加权平均净资产收益率(%) Weighted average return on net assets (%)	1.87	增加0.52个百分点 Increase of 0.52%	4.61	增加1.88个百分点 Increase of 1.88%
		本报告期末 End of the current reporting period	上年度末 End of the previous year	本报告期末比上年度末增 减变动幅度(%) Change in the current reporting period over the end of the previous year (%)
总资产 Total assets		12,221,620,665.54	11,715,023,471.80	4.32
归属于上市公司股东的所有者权益 Owners' equity attributable to shareholders of listed company		11,206,864,334.86	10,742,506,022.92	4.32

注：“本报告期”指本季度初至本季度
末3个月期间，下同。Note: "Current reporting period" refers to the three-month period from
beginning to end of the current quarter, and the same applies hereinafter.

(二) 非经常性损益项目和金额

(II) Items and amounts of non-recurring gains and losses

单位：元 币种：人民币
Unit: RMB

非经常性损益项目	Items of non-recurring gains and losses	本期金额 Amount for the current reporting period	年初至报告期末金额 Beginning of the year to the end of the reporting period	说明 Note
非流动性资产处置损益，包括已计提资产减值准备的冲销部分	Gains and losses on disposal of non-current assets, including the reversal of previously recognized asset impairment provisions	95,018.17	658,359.91	
计入当期损益的政府补助，但与公司正常经营业务密切相关、符合国家政策规定、按照确定的标准享有、对公司损益产生持续影响的政府补助除外	Government grants recognized in profit or loss for the current period, excluding those closely related to the Company's business, in compliance with national policy regulations, received according to established criteria, and having a continuous impact on the Company's profit or loss	650,404.30	4,693,508.14	
除同公司正常经营业务相关的有效套期保值业务外，非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益	Gains and losses from changes in the fair value of financial assets and liabilities held by non-financial corporations, and gains and losses from the disposal of financial assets and liabilities, except for effective hedging operations related to the Company's normal business operations	28,223,506.16	223,753,844.99	
除上述各项之外的其他营业外收入和支出	Non-operating income and expenses other than those listed above	-156,866.42	1,346,645.93	
其他符合非经常性损益定义的损益项目	Other items of profit or loss that meet the definition of non-recurring gains and losses	80,049.20	873,255.46	
减：所得税影响额	Less: Amount affected by income tax	4,370,003.65	34,806,185.84	
合计	Total	24,522,107.76	196,519,428.59	

对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为的非经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。

For items of non-recurring gains and losses that the Company has recognized as items of non-recurring gains and losses not listed in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses" and the amount of which is material, as well as items defined as non-recurring gains and losses in "Interpretative Announcement for Information Disclosure of Companies Issuing Securities No. 1 - Non-recurring Gains and Losses", the reasons shall be explained.

项目	Item	涉及金额 Amount	原因 Reason
递延收益的摊销	Amortization of deferred income	6,898,845.18	本公司将资产相关的政府补助递延收益的摊销认定为经常性损益 The Company recognizes the amortization of deferred income from asset-related government grants as recurring gains and losses

(三) 主要会计数据、财务指标发生变动的情况、原因 (III) Changes in major accounting data and financial indicators, and the reasons therefor

项目名称	Item	变动比例 (%) Percentage of change (%)	主要原因	Main reason
营业收入_本报告期	Operating income_current reporting period	37.61	见表格下方说明。	See note below the table.
归属于上市公司股东的净利润_本报告期	Net profit attributable to shareholders of listed companies_current reporting period	57.47	主要系本报告期营业收入增长所致。	Mainly due to the increase in operating income during the current reporting period.
归属于上市公司股东的净利润_年初至报告期末	Net profit attributable to shareholders of listed companies_from the beginning of the year to the end of the reporting period	90.36	主要系年初至报告期末营业收入、交易性金融资产公允价值变动收益较上年同期大幅增长所致。	Mainly due to the significant increase in operating income and fair value change income of trading financial assets from the beginning of the year to the end of the reporting period compared with the same period last year.
归属于上市公司股东的扣除非经常性损益的净利润_本报告期	Net profit attributable to shareholders of listed companies after deduction of non-recurring profits or losses_current reporting period	50.79	主要系本报告期营业收入增长所致。	Mainly due to the increase in operating income during the current reporting period.
归属于上市公司股东的扣除非经常性损益的净利润_年初至报告期末	Net profit attributable to shareholders of listed companies after deduction of non-recurring profits or losses_from the beginning of the year to the end of the reporting period	38.64	主要系年初至报告期末营业收入、交易性金融资产公允价值变动收益较上年同期大幅增长所致。	Mainly due to the significant increase in operating income and fair value change income of trading financial assets from the beginning of the year to the end of the reporting period compared with the same period last year.
经营活动产生的现金流量净额_年初至报告期末	Net cash flows from operating activities_from the beginning of the year to the end of the reporting period	不适用 N/A	年初至报告期末经营活动现金流量净额较上年增加5.42亿元，主要系报告期销售商品、提供劳务收到的现金增加所致。	The net cash flow from operating activities increased by RMB 542 million from the beginning of the year to the end of the reporting period over the previous year, which was mainly due to the increase in cash received from the sale of goods and the provision of labor services during the reporting period.

基本每股收益(元/股) _本报告期	Basic earnings per share_ current reporting period	45.83	主要系本报告期归属于上市公司股东的净利润增加所致。	Mainly due to the increase in net profit attributable to shareholders of the listed company for the current reporting period.
基本每股收益_年初至报告期末	Basic earnings per share_ from the beginning of the year to the end of the reporting period	80.85	主要系年初至报告期末归属于上市公司股东的净利润增加所致。	Mainly due to the increase in net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period.
稀释每股收益_本报告期	Diluted earnings per share_ current reporting period	45.83	主要系本报告期归属于上市公司股东的净利润增加所致。	Mainly due to the increase in net profit attributable to shareholders of the listed company for the reporting period.
稀释每股收益_年初至报告期末	Diluted earnings per share_ from the beginning of the year to the end of the reporting period	80.85	主要系年初至报告期末归属于上市公司股东的净利润增加所致。	Mainly due to the increase in net profit attributable to shareholders of the listed company from the beginning of the year to the end of the reporting period.

说明：

营业收入_本报告期变动原因：

2024年第三季度，营业收入为9.30亿元，与上年同期相比增加2.54亿元。2024年前三季度，营业收入为22.45亿元，与上年同期相比增加3.39亿元。公司国内外收入均实现增长，具体情况如下：

Note:

The reasons for the changes in operating income_current reporting period are as follows:

In the third quarter of 2024, operating income was RMB 930 million, an increase of RMB 254 million compared to the same period last year. In the first three quarters of 2024, the operating income was RMB 2.245 billion, an increase of RMB 339 million compared with the same period last year. The Company's domestic and international revenues both achieved growth, with the details as follows:

营业收入分地区情况
Operating income by region

单位：亿元

Unit: RMB 100 million

分地区 Region	2024年第三季度 Operating income for the third quarter of 2024			2024年前三季度 Operating income for the first three quarters of 2024		
	金额 Amount	同期变动额 Change amount for the same period	同期变动率 Change rate for the same period	金额 Amount	同期变动额 Change amount for the same period	同期变动率 Change rate for the same period
国内-销售收入 Domestic - Sales revenue	6.80	1.24	22.25%	18.68	2.39	14.64%
国际-销售收入 International - Sales revenue	1.17	0.49	72.10%	2.42	0.66	37.63%
国际-特许经营权服务收入 International - Franchise service income	1.33	0.81	156.85%	1.35	0.35	34.49%
营业收入合计 Total operating income	9.30	2.54	37.61%	22.45	3.39	17.81%


注：表中数据尾差是由于四舍五入所致。

Note: The discrepancies in the table data are due to rounding.

(1) 国内收入增长稳健。2024年第三季度，国内收入为6.80亿元，较上年同期增加1.24亿元，较上年同期增长22.25%，主要归因于公司制剂产品价格的上涨。2024年前三季度，公司实现国内销售收入18.68亿元，较上年同期增长2.39亿元，其中国内制剂销售收入18.02亿元，较上年同期增长2.21亿元。2024年第二季度，公司积极参加了国家组织的全国药品集中采购(胰岛素专项接续)的投标工作，所有产品均成功中选。本次集采公司中选产品价格上涨。新一轮胰岛素集采在二、三季度陆续由各省开始执行，公司产品价格上涨带来的收入增长效应在三季度初步部分体现。具体而言，价格上涨对2024年前三季度公司收入产生了积极影响，使得总收入增加了1.50亿元，详见图1。

(1) Domestic revenue has shown steady growth. In the third quarter of 2024, domestic revenue was RMB 680 million, an increase of RMB 124 million from the same period last year representing a growth of 22.25%, mainly due to the increase in the price of the Company's preparation products. In the first three quarters of 2024, the Company achieved domestic sales revenue of RMB 1.868 billion, an increase of RMB 239 million over the same period of last year, of which the sales revenue of domestic preparations was RMB 1.802 billion, an increase of RMB 221 million over the same period of last year. In the second quarter of 2024, the Company actively participated in the bidding for the national organized centralized drug procurement (insulin-specific continuation), successfully winning all product selections. The price of the selected products of the Company increased in this round of centralized procurement. The new round of insulin centralized procurement started to be implemented by provinces one after another in the second and third quarters, and the revenue growth effect of the Company's product price increase was partially reflected in the third quarter. Specifically, the price increase positively impacted the Company's revenue in the first three quarters of 2024, resulting in an increase of RMB 150 million in total revenue, as detailed in Figure 1.

图1：国内制剂收入变动因素分析
Figure 1: Analysis of factors influencing domestic preparation revenue changes



注释：

销量影响= (2024年1-9月销售量-2023年1-9月销售量) * 2023年1-9月平均单价；价格影响= (2024年1-9月平均价格-2023年1-9月平均价格) * 2024年1-9月销售量。

Note:

Sales volume impact = (Sales volume of Jan. to Sept. in 2024 - Sales volume of Jan. to Sept. in 2023) * Average unit price of Jan. to Sept. in 2023; Price impact = (Average unit price of Jan. to Sept. in 2024 - Average unit price of Jan. to Sept. in 2023) * Sales volume of Jan. to Sept. in 2024

此外，公司在新一轮胰岛素集采中获得首年协议量4,686万支，较上次集采增长32.6%。本次集采执行对公司来说是一个重要的机遇，公司凭借高品质药品与优良配套服务，将通过专业学术推广团队稳步实施市场下沉战略，旨在进一步扩大产品覆盖面，提升市场份额，促进制剂产品销量的增长。随着集采政策的深入执行，公司有望继续享受价格上涨及集采协议量增加带来的双重红利，推动业绩的持续稳定增长。

Additionally, the Company has secured a first-year contract volume of 46.86 million units in the new round of insulin centralized procurement, representing an increase of 32.6% compared with the last round of centralized procurement. The implementation of this round of centralized procurement presents a significant opportunity for the Company. Leveraging high-quality products and excellent supporting services, the Company will steadily implement the market penetration strategy through the professional academic promotion team, aiming to further expand product coverage, increase market share and boost preparation product sales. With the deepening of the centralized procurement policies, the Company is expected to continue benefiting from dual advantages of price increases and increased procurement contract volumes, driving sustained and stable growth in performance.

(2) 新兴市场拓展成效显著。通过持续的产品质量优化和客户服务提升，

(2) The expansion into emerging markets has yielded significant results. Through continuous product quality optimization and

公司赢得更多国际客户的信任和订单，进一步巩固和扩大在国际市场的份额。2024年前三季度，国际销售订单增加，国际销售收入为2.42亿元，较上年同期增长37.63%。其中，第三季度销售收入较上年同期增长72.10%。

值得一提的是，继2024年7月，本土化灌装生产的门冬胰岛素注射液预填充笔及门冬胰岛素30注射液预填充笔获得阿尔及利亚医药监管机构的注册批件，公司出口至阿尔及利亚的订单已在第三季度完成发货，标志着甘李药业在非洲市场的首次本土化项目成功落地。

(3) 欧美市场合作开发取得新进展。2024年前三季度，公司特许经营权服务收入为1.35亿元，较上年同期增长34.49%，主要系公司按照协议约定确认的里程碑节点收入增加所致。

customer service enhancement, the Company won more trust and orders from international clients, further consolidating and expanding the market share in the international arena. During the first three quarters of 2024, international sales orders increased with international sales revenue amounted to RMB 242 million, a year-on-year increase of 37.63%. In particular, sales revenue in the third quarter increased by 72.10% compared to the same period of the previous year.

Notably, following the registration approval from Algeria's pharmaceutical regulatory agency in July 2024, the domestically produced insulin aspart injection pre-filled pen and insulin aspart 30 injection pre-filled pen have been registered. The Company's orders for export to Algeria were shipped in the third quarter, marking the successful implementation of Gan & Lee Pharmaceuticals' first localization project in the African market.

(3) New progress has been made in the cooperative development of the EU and the US markets. In the first three quarters of 2024, the Company's franchise service revenue was RMB 135 million, an increase of 34.49% compared with the same period of the previous year. This growth is primarily attributed to the increase in milestone revenue recognized in accordance with the agreement.

股东信息

Shareholder Information



二、股东信息

II Shareholder information

(一) 普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表

(I) Total number of ordinary shareholders and the number of preferred shareholders with voting rights restored, and the top ten shareholders' shareholdings

单位：股
Unit: Share

报告期末普通股股东总数	77,899	报告期末表决权恢复的优先股股东总数(如有)	0				
Total number of ordinary shareholders at the end of the current reporting period		Total number of preferred shareholders with voting rights restored at the end of the current reporting period (if any)					
前10名股东持股情况(不含通过转融通出借股份) Shareholdings of top ten shareholders (excluding lending of shares through a swap)							
股东名称 Shareholder name	股东性质 Nature of shareholders	持股数量 Number of shares held	持股比例(%) Shareholding ratio (%)	持有有限售条件股份数量 Number of restricted shares held	质押、标记或冻结情况 Status of shares pledged, tagged, or frozen	股份状态 Share status	数量 Number
甘忠如 Zhongru Gan	境内自然人 Domestic natural person	205,643,757	34.21	28,508,550	质押 Pledged		63,260,000
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co.,Ltd	境内非国有法人 Domestic non-state-owned legal entity	47,494,437	7.90		质押 Pledged		10,900,000
明华创新技术投资(香港)有限公司 MING HUA TECHNOLOGY INVESTMENT (HK) LIMITED	境外法人 Overseas legal entity	16,142,079	2.69	15,875,800	无 None		
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	其他 Other	10,367,139	1.72		无 None		
甘喜茹 Xiru Gan	境内自然人 Domestic natural person	6,223,276	1.04		无 None		
Vast Wintersweet Limited	境外法人 Overseas legal entity	6,045,405	1.01	5,777,913	无 None		
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund	其他 Other	5,670,900	0.94		无 None		
中国农业银行股份有限公司－中证500交易型开放式指数证券投资基金 Agricultural Bank of China Limited - CSI 500 Exchange Traded Open-End Index Securities Investment Fund	其他 Other	5,203,828	0.87		无 None		
Hillhouse G&L Holdings (HK) Limited	境外法人 Overseas legal entity	4,357,832	0.73	4,296,032	无 None		
STRONG LINK INTERNATIONAL LIMITED	国有法人 State-owned legal entity	4,256,033	0.71	4,256,033	无 None		

单位：股
Unit: Share

前10名无限售条件股东持股情况(不含通过转融通出借股份)
Shareholdings of the top ten shareholders with unlimited trading conditions

股东名称 Shareholder name	持有无限售条件流通股的 数量 Number of unlimited shares outstanding	股份种类及数量 Category and number of shares	
		股份种类 Category	数量 Number
甘忠如 Zhongru Gan	177,135,207	人民币普通股 RMB ordinary shares	177,135,207
北京旭特宏达科技有限公司 Beijing Xute Hongda Technology Co.,Ltd	47,494,437	人民币普通股 RMB ordinary shares	47,494,437
香港中央结算有限公司 Hong Kong Securities Clearing Company Limited	10,367,139	人民币普通股 RMB ordinary shares	10,367,139
甘喜茹 Xiru Gan	6,223,276	人民币普通股 RMB ordinary shares	6,223,276
中国银行股份有限公司－招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund	5,670,900	人民币普通股 RMB ordinary shares	5,670,900
中国农业银行股份有限公司－中证500交易型开放式指数证券投资基金 Agricultural Bank of China Limited - CSI 500 Exchange Traded Open-End Index Securities Investment Fund	5,203,828	人民币普通股 RMB ordinary shares	5,203,828
张加珍 Jiazhen Zhang	3,913,000	人民币普通股 RMB ordinary shares	3,913,000
中国建设银行股份有限公司－华安聚优精选混合型证券投资基金 China Construction Bank Corporation - Hua'an JuYou Select Mixed Securities Investment Fund	3,673,218	人民币普通股 RMB ordinary shares	3,673,218
中国农业银行股份有限公司－鹏华医药科技股票型证券投资基金 Agricultural Bank of China Limited - Penghua Pharmaceutical Technology Equity Fund	3,246,500	人民币普通股 RMB ordinary shares	3,246,500
中国人寿保险股份有限公司－传统－普通保险产品－005L-CT001沪 China Life Insurance Company Limited - Traditional - Ordinary Insurance Product - 005L - CT001 Shanghai	2,700,900	人民币普通股 RMB ordinary shares	2,700,900

上述股东关联关系或一致行动的说明

Explanation of the above shareholders' affiliation or concerted action

公司控股股东、实际控制人甘忠如持有旭特宏达65.02%的股权；甘喜茹为甘忠如胞妹。除以上情况外，其他股东之间不存在关联关系或一致行动。Zhongru Gan, the controlling shareholder and actual controller of the Company, holds 65.02% of the shares of Beijing Xute Hongda Technology Co.,Ltd. Xiru Gan is the sibling of Zhongru Gan. Apart from the above, there is no affiliation or concerted action among other shareholders.

前10名股东及前10名无限售股东参与融资融券及转融通业务情况说明(如有)

Explanation on the participation of the top ten shareholders and the top ten unlimited shareholders in the margin financing and lending of shares in the transfer and refinancing business (if any)

详见下表
See the table below

持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况
Participation of shareholders holding 5% or more of shares, the top 10 shareholders, and the top 10 shareholders with unlimited shares in circulation in lending of shares in the transfer and refinancing business

股东名称(全称) Shareholder name (full name)	期初普通账户、信用账户持股 General and credit account holdings at the beginning of the current period		期初转融通出借股份且尚未归还 Shares lent in the transfer and refinancing business and has not yet been returned at the beginning of the current period		期末普通账户、信用账户持股 General and credit account holdings at the end of the current period		期末转融通出借股份且尚未归还 Shares lent in the transfer and refinancing business and has not yet been returned at the end of the current period	
	数量合计 Total quantity	比例(%) Proportion (%)	数量合计 Total quantity	比例(%) Proportion (%)	数量合计 Total quantity	比例(%) Proportion (%)	数量合计 Total quantity	比例(%) Proportion (%)
中国银行股份有限公司—招商国证生物医药指数分级证券投资基金 Bank of China Limited - China Merchants CSI Biomedical Index Split-level Securities Investment Fund	3,788,600	0.64	933,200	0.16	5,670,900	0.94		

季度财务报表

Quarterly Financial Statements



三、季度财务报表

III Quarterly Financial Statements

(一) 财务报表

(I) Financial statements

合并资产负债表
Consolidated statement of financial position

2024年9月30日
September 30, 2024

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2024年9月30日 September 30, 2024	2023年12月31日 December 31, 2023
流动资产:	Current Assets:		
货币资金	Cash and Cash equivalents	3,500,170,909.85	2,442,708,603.20
交易性金融资产	Financial assets held for trading	1,566,687,110.23	2,410,429,796.82
应收账款	Accounts receivable	260,952,578.28	383,735,270.90
应收款项融资	Financing receivables	10,440,234.86	1,634,782.89
预付款项	Prepayments	65,038,178.77	40,979,491.54
其他应收款	Other receivables	4,067,790.39	3,491,907.62
存货	Inventories	1,028,209,422.59	860,506,306.14
其他流动资产	Other current assets	52,855,270.58	32,263,551.43
流动资产合计	Total current assets	6,488,421,495.55	6,175,749,710.54
非流动资产:	Non-current Assets:		
债权投资	Debt investment	493,279,827.63	304,658,333.33
其他非流动金融资产	Other non-current financial assets	30,000,000.00	30,000,000.00
固定资产	Fixed assets	2,583,228,479.48	1,872,067,763.13
在建工程	Construction in progress	1,287,823,201.59	2,006,961,148.27
使用权资产	Right-of-use assets	4,571,212.05	6,592,364.52
无形资产	Intangible assets	273,217,267.63	278,082,595.92
开发支出	Development expenditures	831,881,020.70	813,105,292.99
长期待摊费用	Long-term amortized expenses	7,541,098.04	8,868,054.70
递延所得税资产	Deferred tax assets	165,060,138.61	168,953,020.84
其他非流动资产	Other non-current assets	56,596,924.26	49,985,187.56
非流动资产合计	Total non-current assets	5,733,199,169.99	5,539,273,761.26
资产总计	Total assets	12,221,620,665.54	11,715,023,471.80
流动负债:	Current Liabilities		
应付账款	Accounts payable	111,039,231.91	105,541,739.99
合同负债	Contract liabilities	52,257,417.95	52,991,852.39
应付职工薪酬	Payroll and employee benefits payable	167,505,096.69	139,761,214.89

合并资产负债表 (续)
Consolidated statement of financial position (Continued)

项目	Item	2024年9月30日 September 30, 2024	2023年12月31日 December 31, 2023
应交税费	Taxes payable	18,813,663.80	16,910,777.27
其他应付款	Other payables	454,180,202.82	454,009,437.80
其中：应付股利	Of which: Dividends payables	1,965,508.00	
一年内到期的非流动负债	Non-current liabilities due within one year	2,361,167.58	3,958,443.73
其他流动负债	Other current liabilities	517,838.22	275,580.81
流动负债合计	Total current liabilities	806,674,618.97	773,449,046.88
非流动负债：	Non-current Liabilities:		
租赁负债	Lease liabilities	3,672,433.54	5,447,249.65
长期应付款	Long-term payables	11,420,438.19	13,995,107.23
预计负债	Provisions		
递延收益	Deferred income	171,126,795.22	179,625,640.40
递延所得税负债	Deferred tax liabilities	21,862,044.76	
非流动负债合计	Total non-current liabilities	208,081,711.71	199,067,997.28
负债合计	Total liabilities	1,014,756,330.68	972,517,044.16
所有者权益(或股东权益)：	Owners' (or Shareholders') equity:		
实收资本(或股本)	Paid-in capital (or share capital)	601,065,290.00	594,161,750.00
资本公积	Capital reserve	3,551,504,399.45	3,350,753,839.87
减：库存股	Less: Treasury share	200,846,739.31	71,364,020.00
其他综合收益	Other comprehensive income	2,952,172.83	3,817,428.85
盈余公积	Surplus reserve	300,532,645.00	297,080,875.00
未分配利润	Retained earnings	6,951,656,566.89	6,568,056,149.20
归属于母公司所有者权益(或股东权益)合计	Total owner's equity (or shareholders' equity) attributable to the parent company	11,206,864,334.86	10,742,506,022.92
少数股东权益	Non-controlling interests		404.72
所有者权益(或股东权益)合计	Total owners' (or shareholders') equity	11,206,864,334.86	10,742,506,427.64
负债和所有者权益(或股东权益)总计	Total liabilities and owners' (or Shareholders') equity	12,221,620,665.54	11,715,023,471.80

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

合并利润表

Consolidated income statement

2024年1—9月
Jan. to Sept., 2024编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2024年前三季度(1-9月) First three quarters of 2024 (Jan. to Sept.)	2023年前三季度(1-9月) First three quarters of 2023 (Jan. to Sept.)
一、营业总收入	I. Total Revenue	2,245,006,087.12	1,905,670,877.67
其中:营业收入	Of which: Operating income	2,245,006,087.12	1,905,670,877.67
二、营业总成本	II. Total operating costs	1,921,772,067.24	1,645,843,381.45
其中:营业成本	Of which: Operating costs	553,241,458.86	481,189,719.14
税金及附加	Taxes and surcharges	22,246,574.82	17,933,843.14
销售费用	Selling expenses	831,334,688.22	703,633,555.05
管理费用	General and administrative expenses	169,962,996.50	141,626,147.56
研发费用	R&D expenses	403,442,931.89	369,945,734.16
财务费用	Financial expenses	-58,456,583.05	-68,485,617.60
加:其他收益	Add: Other income	14,065,608.78	13,936,831.47
投资收益(损失以“—”号填列)	Investment income or loss (loss is indicated with "-")	55,851,319.43	59,839,944.90
公允价值变动收益(损失以“—”号填列)	Gain or loss on the changes in fair value (loss is indicated with "-")	167,902,884.11	-17,576,525.82
信用减值损失(损失以“—”号填列)	Credit impairment losses (loss is indicated with "-")	529,401.96	4,492,847.21
资产减值损失(损失以“—”号填列)	Assets impairment losses (loss is indicated with "-")	16,817.47	-3,352,763.40
资产处置收益(损失以“—”号填列)	Gain or loss from disposal of assets (loss is indicated with "-")	658,001.36	45,822.47
三、营业利润(亏损以“—”号填列)	III. Operating Profit (loss is indicated with "-")	562,258,052.99	317,213,653.05
加:营业外收入	Add: Non-operating income	2,164,705.30	2,931,333.37
减:营业外支出	Less: Non-operating expenses	818,059.37	9,123,853.22
四、利润总额(亏损总额以“—”号填列)	IV. Profit before tax (loss is indicated with "-")	563,604,698.92	311,021,133.20
减:所得税费用	Less: Income tax expense	56,339,499.40	44,545,285.75
五、净利润(净亏损以“—”号填列)	V. Net Profit (loss is indicated with "-")	507,265,199.52	266,475,847.45
(一)按经营持续性分类	(I) Categorized by operation continuity		
1.持续经营净利润(净亏损以“—”号填列)	1. Net profit from continuing operations (net loss is indicated with "-")	507,265,199.52	266,475,847.45

合并利润表 (续)
Consolidated income statement (Continued)

项目	Item	2024年前三季度 (1-9月) First three quarters of 2024 (Jan. to Sept.)	2023年前三季度 (1-9月) First three quarters of 2023 (Jan. to Sept.)
(二) 按所有权归属分类	(II) Categorized by ownership		
1. 归属于母公司股东的净利润 (净亏损以“-”号填列)	1. Net profit attributable to owners of the parent company (net loss is indicated with "-")	507,265,245.69	266,475,880.66
2. 少数股东损益 (净亏损以“-”号填列)	2. Net profit attributable to non-controlling interests (net loss is indicated with "-")	-46.17	-33.21
六、其他综合收益的税后净额	VI. Other comprehensive income net of tax	-865,256.02	869,456.92
(一) 归属母公司所有者的其他综合收益的税后净额	(I) Other comprehensive income, net of tax, attributable to owners of the parent company	-865,256.02	869,456.92
1. 不能重分类进损益的其他综合收益	1. Other comprehensive income cannot be reclassified to profit or loss		
2. 将重分类进损益的其他综合收益	2. Other comprehensive income to be reclassified to profit or loss	-865,256.02	869,456.92
(1) 外币财务报表折算差额	(1) Exchange differences on translation of foreign currency financial statements	-865,256.02	869,456.92
(二) 归属于少数股东的其他综合收益的税后净额	(II) Other comprehensive income net of tax attributable to non-controlling interests		
七、综合收益总额	VII. Total Comprehensive Income	506,399,943.50	267,345,304.37
(一) 归属于母公司所有者的综合收益总额	(I) Total comprehensive income attributable to owners of the parent company	506,399,989.67	267,345,337.58
(二) 归属于少数股东的综合收益总额	(II) Total comprehensive income attributable to non-controlling interests	-46.17	-33.21
八、每股收益：	VIII. Earnings Per Share:		
(一) 基本每股收益(元/股)	(I) Basic earnings per share (RMB per share)	0.85	0.47
(二) 稀释每股收益(元/股)	(II) Diluted earnings per share (RMB per share)	0.85	0.47

本期发生同一控制下企业合并的，被合并方在合并前实现的净利润为：0元，上期被合并方实现的净利润为：0元。

As for a business combination under the same control in the current period, the net profit generated by the merged party before the combination was RMB 0, and that generated during the previous period was RMB 0.

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

合并现金流量表

Consolidated statement of cash flows

2024年1—9月
Jan. to Sept., 2024

编制单位:甘李药业股份有限公司
Prepared by: Gan & Lee Pharmaceuticals.

单位:元 币种:人民币 审计类型:未经审计
Unit: RMB Audit type: Unaudited

项目	Item	2024年前三季度(1-9月) First three quarters of 2024 (Jan. to Sept.)	2023年前三季度(1-9月) First three quarters of 2023 (Jan. to Sept.)
一、经营活动产生的现金流量: I. Cash Flows from Operating Activities:			
销售商品、提供劳务收到的现金	Cash receipts from the sale of goods and the rendering of services	2,405,077,571.10	1,694,545,146.87
收到的税费返还	Tax refunds received	67,547,714.01	60,108,069.51
收到其他与经营活动有关的现金	Cash received relating to other operating activities	9,914,697.24	18,298,113.92
经营活动现金流入小计	Subtotal of cash inflows from operating activities	2,482,539,982.35	1,772,951,330.30
购买商品、接受劳务支付的现金	Cash paid for purchase of goods and services	641,934,128.62	583,746,062.18
支付给职工及为职工支付的现金	Cash paid to and on behalf of employees	639,530,019.39	560,703,892.71
支付的各项税费	Cash paid for taxes	81,065,798.62	18,810,397.10
支付其他与经营活动有关的现金	Cash paid relating to other operating activities	654,669,741.87	686,647,237.11
经营活动现金流出小计	Subtotal of cash outflows from operating activities	2,017,199,688.50	1,849,907,589.10
经营活动产生的现金流量净额	Net cash flows from operating activities	465,340,293.85	-76,956,258.80
二、投资活动产生的现金流量: II. Cash Flows from Investing Activities:			
收回投资收到的现金	Cash received from recovery of investments	7,070,151,578.75	5,624,282,000.44
取得投资收益收到的现金	Cash receipts from investment income	21,503,965.64	275,784,951.06
处置固定资产、无形资产和其他长期资产收回的现金净额	Net proceeds from disposal of fixed assets, intangible assets, and other long-term assets		190,000.00
收到其他与投资活动有关的现金	Other cash received related to investing activities	2,484,645.75	14,409,970.30
投资活动现金流入小计	Subtotal of cash inflows from investing activities	7,094,140,190.14	5,914,666,921.80
购建固定资产、无形资产和其他长期资产支付的现金	Purchase of fixed assets, intangible assets, and other non-current assets	294,762,231.72	346,811,677.15
投资支付的现金	Cash paid for investments	7,279,256,512.68	5,448,209,000.03

合并现金流量表 (续)
Consolidated statement of cash flows (Continued)

项目	Item	2024年前三季度 (1-9月) First three quarters of 2024 (Jan. to Sept.)	2023年前三季度 (1-9月) First three quarters of 2023 (Jan. to Sept.)
支付其他与投资活动有关的现金	Cash paid relating to other investing activities		46,103,532.84
投资活动现金流出小计	Subtotal of cash outflows from investing activities	7,574,018,744.40	5,841,124,210.02
投资活动产生的现金流量净额	Net cash flows from investing activities	-479,878,554.26	73,542,711.78
三、筹资活动产生的现金流量：	III. Cash Flows from Financing Activities:		
吸收投资收到的现金	Cash received from investment absorption	139,321,600.00	
收到其他与筹资相关的现金	Cash received from other financing activities		
筹资活动现金流入小计	Subtotal of cash inflows from financing activities	139,321,600.00	
分配股利、利润或偿付利息支付的现金	Cash paid for distributing dividends, profits, or repaying interest	118,247,550.00	
支付其他与筹资活动有关的现金	Cash paid relating to other financing activities	19,159,981.31	3,503,968.02
筹资活动现金流出小计	Subtotal of cash outflows from financing activities	137,407,531.31	3,503,968.02
筹资活动产生的现金流量净额	Net cash flow from financing activities	1,914,068.69	-3,503,968.02
四、汇率变动对现金及现金等价物的影响	IV. Effect of exchange rate changes on cash and cash equivalents	-1,572,201.80	3,097,103.59
五、现金及现金等价物净增加额	V. Net increase in cash and cash equivalents	-14,196,393.52	-3,820,411.45
加：期初现金及现金等价物余额	Add: Cash and cash equivalents at the beginning of the current period	286,438,980.59	397,328,882.98
六、期末现金及现金等价物余额	VI. Cash and cash equivalents at the end of the current period	272,242,587.07	393,508,471.53

公司负责人：	甘忠如	主管会计工作负责人：	孙程	会计机构负责人：	周丽
Legal Representative:	Zhongru Gan	Chief Accountant:	Cheng Sun	Head of Accounting Department:	Li Zhou

特此公告

Hereby announced officially.

甘李药业股份有限公司董事会
The Board of Directors of Gan & Lee Pharmaceuticals.

2024年10月21日
October 21, 2024



SCIENCE EXCELLENCE

甘李药业有限公司

Gan & Lee Pharmaceuticals.

地址：北京市通州区漷县镇南凤西一路8号

Address: No. 8, Nanfeng West 1st Street, Huoxian, Tongzhou District, Beijing

网址：<http://www.ganlee.com>

Website: <https://www.ganlee.com.cn>

电话：+86 010-80593699

Tel: +86 010-80593699

邮编：101109

Post code : 101109